Dermatology · Clinical trials
Rosacea Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About rosacea — and why its trials are hard
Rosacea is a chronic inflammatory facial dermatosis marked by centrofacial flushing, persistent erythema, telangiectasia, and inflammatory papules and pustules, sometimes with phymatous change or ocular involvement. Its pathophysiology involves neurovascular dysregulation, an aberrant innate immune response (cathelicidin/LL-37), and the Demodex folliculorum mite. Management is tailored to the dominant features (subtypes): erythematotelangiectatic, papulopustular, phymatous, and ocular. Unlike many dermatologic diseases, rosacea has a mature set of FDA-approved therapies rather than a single breakthrough. Topical agents target inflammatory lesions (metronidazole, azelaic acid, ivermectin) or persistent erythema through alpha-adrenergic vasoconstriction (brimonidine, oxymetazoline), while sub-antimicrobial-dose oral doxycycline provides anti-inflammatory benefit without meaningful antibiotic pressure. More recent additions include encapsulated benzoyl peroxide and topical minocycline foam. Trials are typically judged on the Investigator Global Assessment (IGA) success rate and inflammatory lesion counts, with distinct erythema scales used for the vascular-predominant presentations.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Metronidazole (MetroGel / MetroCream) | 1988 | Topical treatment of inflammatory papules and pustules of rosacea | Multiple randomized vehicle-controlled trials | Reduction in inflammatory lesion count and IGA success | Consistently reduced inflammatory lesions versus vehicle; a long-established first-line topical |
| Azelaic acid (Finacea) | 2002 | Topical treatment of papulopustular rosacea (15% gel/foam) | Phase 3 vehicle-controlled trials | IGA success and change in inflammatory lesion count | Significantly higher treatment success and greater lesion reduction than vehicle |
| Ivermectin (Soolantra) | 2014 | Topical 1% cream for inflammatory lesions of papulopustular rosacea | Phase 3 vehicle-controlled trials (and head-to-head vs metronidazole) | IGA success at week 12 and inflammatory lesion count | Higher IGA success versus vehicle and superior lesion reduction versus topical metronidazole in a comparator study |
| Brimonidine (Mirvaso) | 2013 | Topical 0.33% gel for persistent facial erythema of rosacea | Phase 3 vehicle-controlled trials | Two-grade improvement on both clinician and patient erythema scales | Significantly more patients achieved composite erythema improvement versus vehicle; effect is temporary vasoconstriction |
| Oxymetazoline (Rhofade) | 2017 | Topical 1% cream for persistent facial erythema of rosacea | REVEAL Phase 3 trials | Composite two-grade erythema improvement at hour 3 through day 29 | Significantly higher composite erythema response than vehicle across timepoints |
| Doxycycline (modified-release 40 mg) (Oracea) | 2006 | Oral anti-inflammatory (sub-antimicrobial) dose for papulopustular rosacea | Two Phase 3 trials | Change in inflammatory lesion count and IGA at week 16 | Significantly greater lesion reduction than placebo at a dose below the antibacterial threshold |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in rosacea development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Omiganan — Rosacea development program (Phase 2/3-stage topical cationic peptide) | Despite early positive papulopustular rosacea signals, the program did not advance to FDA approval | Inconsistent efficacy relative to existing topicals and commercial/development discontinuation limited progression (details unverified) |
Choosing the right endpoint
Primary endpoints that matter in rosacea trials
- IGA success — Investigator Global Assessment of 'clear' or 'almost clear' with at least a 2-grade improvement; standard endpoint for papulopustular disease
- Inflammatory lesion count — Absolute or percent change in papules and pustules; co-primary endpoint in papulopustular trials
- Clinician Erythema Assessment — Ordinal severity scale for persistent facial redness used for vascular-predominant agents
- Patient Self-Assessment — Patient-rated erythema/lesion severity, often combined with clinician scores in a composite success endpoint
How iNGENū runs rosacea trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Rosacea clinical trials — FAQs
Which treatment targets redness versus bumps?
Is low-dose doxycycline an antibiotic?
Can rosacea be cured?
Ready to discuss your rosacea trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal